Preparing for an era of untreatable gonorrhea

Current Opinion in Infectious Diseases

Volumn 27, Issue 3, 2014, Pages 282-287

  Barbee, Lindley A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Public Health   (United States)

Author keywords

antimicrobial resistance; extended spectrum cephalosporins; Neisseria gonorrhoeae; novel treatments

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; DOXYCYCLINE; SPECTINOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; COMMENSAL; GONORRHEA; HUMAN; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; PHARYNX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING; SEXUALITY; TREATMENT FAILURE; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; HEALTH SURVEY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PRACTICE GUIDELINE; PUBLIC HEALTH;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; DRUG ADMINISTRATION SCHEDULE; GONORRHEA; HUMANS; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; PHARYNX; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; PUBLIC HEALTH; TREATMENT FAILURE;

EID: 84900474717     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000058     Document Type: Review

References (56)

1. Ison CA, Town K, Obi C, et al. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. Lancet Infect Dis 2013; 13:762-768.
2. Kirkcaldy RD, Kidd S, Weinstock HS, et al. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006-June 2012. Sex Transm Infect 2013; 89 (Suppl 4):iv5-10.
3. Hottes TS, Lester RT, Hoang LM, et al. Cephalosporin and azithromycin susceptibility in Neisseria gonorrhoeae isolates by site of infection, British Columbia, 2006 to 2011. Sex Transm Dis 2013; 40:46-51.
4. Bala M, Kakran M, Singh V, et al. Monitoring antimicrobial resistance in Neisseria gonorrhoeae in selected countries of the WHO South-East Asia Region between 2009 and 2012: a retrospective analysis. Sex Transm Infect 2013; 89 (Suppl 4):iv28-35.
5. CDC. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: US Department of Health and Human Services Centers for Disease Control and Prevention; 2013.
6. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401-1422.
7. Unemo M, Golparian D, Syversen G, et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010; 15:19721.
8. Ison CA, Hussey J, Sankar KN, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011; 16:19833.
9. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibilitytocefixime inToronto Canada. JAMA 2013; 309:163-170.
10. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime-and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273-1280.
11. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538-3545.
12. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366:485-487.
13. Koedijk FD, vanBergen JE, Dukers-Muijrers NH, et al. Thevalueoftestingmultiple anatomic sites for gonorrhoea and chlamydia in sexually transmitted infection centres in the Netherlands, 2006-2010. Int J STD AIDS 2012; 23:626-631.
14. Park J, Marcus JL, Pandori M, et al. Sentinel surveillance for pharyngeal chlamydia and gonorrhea among men who have sex with men-San Francisco, 2010. Sex Transm Dis 2012; 39:482-484.
15. Shaw SG, Hassan-Ibrahim M, Soni S. Are we missing pharyngeal and rectal infections in women by not testing those who report oral and anal sex? Sex Transm Infect 2013; 89:397.
16. Peters RP, Nijsten N, Mutsaers J, et al. Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sex Transm Dis 2011; 38:783-787.
17. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005; 41:67-74.
18. Linhart Y, Shohat T, Amitai Z, et al. Sexually transmitted infections among brothel-based sex workers in Tel-Aviv area, Israel: high prevalence of phar-yngeal gonorrhoea. Int J STD AIDS 2008; 19:656-659.
19. Barbee LA, Dombrowski JC, Kerani RP, Golden MR. Effect of nucleic acid amplification testing on detection of extra-genital gonorrhea and chlamydial infections in MSM STD clinic patients. Sex Transm Dis 2014; 41:168-172.
20. Marcus JL, Bernstein KT, Kohn RP, et al. Infections missed by urethral-only screening for chlamydia or gonorrhea detection among men who have sex with men. Sex Transm Dis 2011; 38:922-924.
21. Workowski KA, Berman S, CDC CfDCaP. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1-110.
22. CDC. Sexually transmitted disease surveillance, 2008. Atlanta, GA: US Department of Health and Human Services; 2009.
23. Weinstock H, Workowski KA. Pharyngeal gonorrhea:animportant reservoir of infection? Clin Infect Dis 2009; 49:1798-1800.
24. Deguchi T, Yasuda M, Ito S. Management of pharyngeal gonorrhea is crucial to prevent the emergence and spread of antibiotic-resistant Neisseria gonor-rhoeae. Antimicrob Agents Chemother 2012; 56:4039-4040.
25. Ameyama S, Onodera S, Takahata M, et al. Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002; 46:3744-3749.
26. Ito M, Deguchi T, Mizutani KS, et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in Central Japan. Antimicrob Agents Chemother 2005; 49:137-143.
27. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20 (Suppl 1):S47-S65.
28. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995; 22:39-47.
29. CDC. Update to CDC'sSexually Transmitted Diseases Treatment Guidelines, 2010. Oral cephalosporins no longer a recommended treatment for gono-coccal infections. MMWR Morb Mortal Wkly Rep 2012; 61:590-594.
30. Bignell C, Fitzgerald M. UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011; 22:541-547.
31. Bignell C, Unemo M, Board E.S.G.E. 2012 Europeanguidelineonthediagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013; 24:85-92.
32. Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections. http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/ section-5-6-eng.php#toc361210470. [Accessed 29 January 2013]
33. Handsfield HH, Murphy VL, Holmes KK. Dose-ranging study of ceftriaxone for uncomplicated gonorrhea in men. Antimicrob Agents Chemother 1981; 20:839-840.
34. CDC. Sexually Transmitted Disease Surveillance, 2011. Atlanta, GA: US Department of Health and Human Services; 2012.
35. Bai ZG, Bao XJ, Cheng WD, et al. Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials. Int J STD AIDS 2012; 23:126-132.
36. Jaffe HW, Schroeter AL, Reynolds GH, et al. Pharmacokinetic determinants of penicillin cure of gonococcal urethritis. Antimicrob Agents Chemother 1979; 15:587-591.
37. Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65:2141-2148.
38. Lewis DA. Global resistance of Neisseria gonorrhoeae: when theory becomes reality. Curr Opin Infect Dis 2014; 27:62-67.
39. Barbee LA, Kerani RP, Dombrowski JC, et al. A retrospective comparative study of two-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis 2013; 56:1539-1545.
40. Sathia L, Ellis B, Phillip S, et al. Pharyngeal gonorrhoea-is dual therapy the way forward? Int J STD AIDS 2007; 18:647-648.
41. Gratrix J, Bergman J, Egan C, et al. Retrospective review of pharyngeal gonorrhea treatment failures in Alberta Canada. Sex Transm Dis 2013; 40:877-879.
42. Ison CA, Deal C, Unemo M. Current and future treatment options for gonorrhoea. Sex Transm Infect 2013; 89 (Suppl 4):iv52-56.
43. Brown LB, Krysiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010; 37:169-172.
44. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Postgrad Med J 2013; 89:142-147.
45. Kirkcaldy R. Treatment of gonorrhea in an era of emerging cephalosporin resistance and results of a randomised trial of new potential treatment options [abstract]. In: STI & AIDS World Congress. Vienna, Austria: Sexually Transmitted Infections; 2013.
46. Unemo M, Golparian D, Limnios A, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse cef-triaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrob Agents Chemother 2012; 56:3603-3609.
47. Furuya R, Koga Y, Irie S, et al. In vitro activities of antimicrobial combinations against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2013; 19:1218-1220.
48. Pereira R, Cole MJ, Ison CA. Combination therapy for gonorrhoea: in vitro synergy testing. J Antimicrob Chemother 2013; 68:640-643.
49. Barbee LA, Soge OO, Holmes KK, Golden MR. In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae. J Antimicrob Chemother 2014. [Epub ahead of print]
50. Golparian D, Fernandes P, Ohnishi M, et al. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012; 56:2739-2742.
51. Huband MD, Flamm RK, Rhomberg PR, et al. In vitro activity of AZD0914: a new benzisoxazole DNA gyrase inhibitor against Neisseria gonorrhoeae [abstract]. Denver, CO: ICAAC; 2013.
52. Balows A, Printz DW. CDC program for diagnosis of gonorrhea. JAMA 1972; 222:1557.
53. Sexton ME, Baker JJ, Nakagawa K, et al. How reliable is self-testing for gonorrhea and chlamydia among men who have sex with men? J Fam Pract 2013; 62:70-78.
54. Goire N, Lahra MM, Ohnishi M, et al. Polymerase chain reaction-based screening for the ceftriaxone-resistant Neisseria gonorrhoeae F89 strain. Euro Surveill 2013; 18:20444.
55. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676-685.
56. Golden M, Barbee L, Kerani R, Dombrowski J. Potential population-level impact of replacing oral gonococcal therapy with intramuscular therapy [abstract]. In: STI & AIDS World Congress. Vienna, Austria: Sexually Transmitted Infections; 2013.